Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
6Customers
2Debt Items
14Related Chains
Source-Backed Evidence Depth
Niagen Bioscience, Inc. (NAGE) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
11Total relationships
3Distinct source URLs
4High confidence
0.733Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Niagen Bioscience, Inc. Suppliers
Ticker
Name
Confidence
Evidence
QUEEN-S-UNIVERSITY-BELFAST
QUEEN-S-UNIVERSITY-BELFAST
92%
Under the Agreement, QUB assigned to the Company all of QUB's right, title, and interest in the patent rights previously jointly owned or licensed to the Company under the JOMA and the License Agreement.
Reciprocal relationship from OPK graph: ence over the particular investee and whether the particular equity security has a readily determinable fair value. We have determined that our ownership in th…
Niagen Bioscience, Inc. Customers
Ticker
Name
Confidence
Evidence
ELYSIUM-HEALTH-INC
ELYSIUM-HEALTH-INC
62%
roduct recall could result in substantial and unexpected expenditures, which would reduce operating profit and cash flow. In addition, a product recall may require significant management attention. P…
ELYSIUM-HEALTH-LLC
ELYSIUM-HEALTH-LLC
62%
roduct recall could result in substantial and unexpected expenditures, which would reduce operating profit and cash flow. In addition, a product recall may require significant management attention. P…
NESTEC-LTD
NESTEC-LTD
62%
ter. Under the terms of the arrangement, the parties agreed to resolve previously withheld receivables totaling approximately $ 1.3 million, the full balance was received by the Company as of the end…
ROTH-CAPITAL-PARTNERS-LLC
ROTH-CAPITAL-PARTNERS-LLC
62%
. If they do so again, we may be forced to respond by lowering our prices. This would reduce sales revenues and increase losses. Failure to anticipate and respond to price competition may also impact…
THORNE-HEALTHTECH-INC
THORNE-HEALTHTECH-INC
62%
ter. Under the terms of the arrangement, the parties agreed to resolve previously withheld receivables totaling approximately $ 1.3 million, the full balance was received by the Company as of the end…
THORNE-RESEARCH-INC
THORNE-RESEARCH-INC
62%
ter. Under the terms of the arrangement, the parties agreed to resolve previously withheld receivables totaling approximately $ 1.3 million, the full balance was received by the Company as of the end…
Niagen Bioscience, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
NAGE-DEBT
Debt stack $2.6M
90%
Market cache reports total debt of $2.6M.
NAGE-DEBT-11159
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2019-12-31.
Niagen Bioscience, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Niagen Bioscience, Inc..
Niagen Bioscience, Inc. Ownership
Holder
Name
Confidence
Evidence
NAGE-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 147 tracked holders.
Niagen Bioscience, Inc. Extended Supply Chain Network
